newsfilter
← Latest News
GlobeNewswire·

Mural Oncology Announces Plans to Explore Strategic Alternatives

Following review of data from the phase 2 ARTISTRY-6 trial and previously announced results from the phase 3 ARTISTRY-7 trial, Mural will discontinue all clinical development of nemvaleukin With $144.4 million in cash